ErbB2, FoxM1 and 14-3-3ζ prime breast cancer cells for invasion in response to ionizing radiation

Oncogene

Volumn 33, Issue 5, 2014, Pages 589-598

  Kambach, D M ^a   Sodi, V L ^a   Lelkes, P I ^b   Azizkhan Clifford, J ^a   Reginato, M J ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b DREXEL UNIVERSITY   (United States)

Author keywords

14 3 3z; ErbB2; FoxM1; invasion; reactive oxygen species

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ANTIOXIDANT; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELATINASE A; LAPATINIB; PROTEIN 14 3 3; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; TYROSINE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IONIZING RADIATION; IRRADIATION; ONCOGENE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; X RAY;

14-3-3 PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MATRIX METALLOPROTEINASE 2; MCF-7 CELLS; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION, IONIZING; REACTIVE OXYGEN SPECIES; RECEPTOR, ERBB-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84887508030     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.629     Document Type: Article

References (56)

1. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ. Tyrosine kinase signaling in breast cancer: Epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2000; 2: (Journal Article) 203-210.
2. Badache A, Goncalves A. The ErbB2 signaling network as a target for breast cancer therapy. J Mammary Gland Biol Neoplasia 2006; 11: 13-25.
3. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
4. DiGiovanna MP, Chu P, Davison TL, Howe CL, Carter D, Claus EB et al. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ. Cancer Res 2002; 62: 6667-6673.
5. Garrett TPJ, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003; 11: 495-505.
6. Olayioye MF, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 2000; 19: 3159-3167.
7. Schmidt-Ullrich R, Valerie K, Fogleman PB, Walters J. Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat Res 1996; 145: 81-85.
8. Mikkelsen RB, Contessa JN, Abell A, Valerie K, Schmidt-Ullrich RK. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation. Br Ca Res and Treat 2006; 95: 17-27.
9. Tofilon PJ, Camphausen K. Molecular targets for tumor radiosensitization. Chem Rev 2009; 109: 2974-2988.
10. Bowers G, Reardon D, Hewitt T, Dent P, Mikkelsen RB, Valerie K et al. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene 2001; 20: 1388-1397.
11. Andarawewa K, Erickson A, Chou W, Costes S, Gascard P, Mott J et al. Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition. Cancer Res 2007; 67: 8662-8670.
12. Lagadec C, Vlashi E, Della Donna L, Dekmezian C, Pajonk F. Radiation-induced reprogramming of breast cancer cells. Stem Cells 2012; 30: 833-844.
13. Mori K, Shibanuma M, Nose K. Invasive potential induced under long-term oxidative stress in mammary epithelial cells. Cancer Res 2004; 64: 7464-7472.
14. Kalin TV, Wang IC, Ackerson TJ, Major ML, Detrisac CJ, Kalinichenko VV et al. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res 2006; 66: 1712-1720.
15. Caldwell SA, Jackson SR, Shahriari KS, Lynch TP, Sethi G, Walker S et al. Nutrient sensor O-GlcNac transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1. Oncogene 2010; 29: 2831-2842.
16. Bektas N, Haaf A, Veeck J, Wild PJ, Luscher-Firzlaff J, Hartmann A et al. Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer. BMC Cancer 2008; 8: 42.
17. Francis RE, Myatt SS, Krol J, Hartman J, Peck B, McGovern UB et al. FoxM1 is a target and downstream marker of HER2 overexpression in breast cancer. Int J Onc 2009; 35: 57-68.
18. Carr JR, Park HJ, Wang Z, Kiefer MM, Rachaudhuri P. FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res 2010; 70: 5054-5063.
19. Raychaudhuri P, Park HJ. FoxM1: A master regulator of tumor metastasis. Cancer Res 2011; 71: 4329-4333.
20. Neal CL, Yao J, Yang W, Zhou X, Nguyen NT, Lu J et al. 14-3-3z overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res 2009; 69: 3425-3432.
21. Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B et al. 14-3-3 Cooperates with ErbB2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial-mesenchymal transition. Cancer Cell 2009; 16: 195-207.
22. Danes CG, Wyszomierski SL, Lu J, Neal CL, Yang W, Yu D. 14-3-3z Down-regulates p53 in mammary epithelial cells and confers luminal filling. Cancer Res 2008; 68: 1760-1767.
23. Muthuswamy S, Xiang B. Using three-dimensional acinar structures for molecular and cell biological assays. Methods Enzymol 2006; 406: 692.
24. Hebner C, Weaver VM, Debnath J. Modeling morphogenesis and oncogenesis in three-dimensional breast epithelial cultures. Annu Rev Pathol 2008; 3: 313-339.
25. Haenssen KK, Caldwell SA, Shahriari KS, Jackson SR, Whelan KA, Klein-Szanto AJ et al. ErbB2 requires integrin a5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells. J Cell Sci 2010; 123: 1373-1382.
26. Muthuswamy SK, Li D, Lielievre S, Bissell MJ, Brugge JS. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 2001; 3: 785-792.
27. Lawrence TS, Haken RKT, Giaccia A. Principles of radiation oncology. In: DeVita VTJ, Lawrence TS, Rosenberg E (eds). DeVita, Hellman, and Rosenbergs Cancer: Principles and Practice of Oncology edn. Lippincott Williams and Wilkins: Philadelphia, 2008, pp 307-336.
28. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007; 4: 359-365.
29. Feinendegen LE. Reactive oxygen species in cell responses to toxic agents. Hu Exp Toxicol 2002; 21: 85-90.
30. Leach JK, Van Tuyle G, Lin P-S, Schmidt-Ullrich RK, Mikkelsen RB. Ionizing radiation-induced, mitochondria-dependent generation of reactive oxygen/nitrogen. Cancer Res 2001; 61: 3894-3901.
31. Sato K, Akaike T, Suga M, Ando M, Maeda H. Generation of free radicals from neocarzinostatin mediated by NADPH/cytochrome P-450 reductase via activation of enediyne chromophore. Biochem Biophys Res Commun 1994; 205: 1716-1723.
32. Giannoni E, Taddei ML, Chiarugi P. Src redox regulation: Again in the front line. Free Radic Biol Med 2010; 49: 516-527.
33. Ishizawar RC, Miyake T, Parsons SJ. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene 2007; 26: 3503-3510.
34. Zhang S, Huang W-C, Li P, Guo H, Poh S-B, Brady SW et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011; 17: 461-470.
35. Tan M, Li P, Klos KS, Lu J, Lan K-H, Nagata Y et al. ErbB2 promotes src synthesis and stability: Novel mechanisms of src activation that confer breast cancer metastasis. Cancer Res 2005; 65: 1585-67.
36. Marcotte R, Zhou L, Kim H, Roskelly CD, Muller WJ. c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential. Mol Cell Biol 2009; 29: 5858-5871.
37. Park HJ, Carr JR, Wang Z, Nogueira V, Hay N, Tyner AL et al. FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J 2009; 28: 2908-2918.
38. Mendes O, Kim H-T, Lungu G, Stoica G. MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2. Clin Exp Metastasis 2007; 24: 341-351.
39. Chabottaux V, Noel A. Breast cancer progression: Insights into multifaceted matrix metalloproteinases. Clin Exp Metastasis 2007; 24: 647-656.
40. Dai B, Kang SH, Gong W, Liu M, Aldape KD, Sawaya R et al. Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. Oncogene 2007; 26: 6212-6219.
41. Ahmad A, Wang Z, Kong D, Ali S, Li Y, Banerjee S et al. FoxM1 down-regulation leads to inhibition of proliferation, migration, and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors. Br Ca Res and Treat 2010; 122: 337-346.
42. Bergamaschi A, Christensen BL, Katzenellenbogen BS. Reversal of endocrine resistance in breast cancer: Interrelationships among 14-3-3z FoxM1, and a gene signature associated with mitosis. Br Ca Res 2011; 13: R70.
43. Millour J, Constantinidou D, Stavropoulou AV, Wilson MSC, Myatt SS, Kwok JMM et al. FOXM1 is a transcriptional target of ER[alpha] and has a critical role in breast cancer endocrine sensitivity and resistance. Oncogene 2010; 29: 2983-2995.
44. Bergamaschi A, Katzenellenbogen BS. Tamoxifen downregulation of miR-451 increases 14-3-3[zeta] and promotes breast cancer cell survival and endocrine resistance. Oncogene 2012; 31: 39-47.
45. Koo C-Y, Muir KW, Lam EWF. FOXM1: From cancer initiation to progression and treatment. Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 2012; 1819: 28-37l.
46. Neal CL, Yu D. 14-3-3z as a prognostic marker and therapeutic target for cancer. Expert Opin Ther Targets 2010; 14: 1343-1354.
47. Tzivion G, Gupta VS, Kaplun L, Balan V. 14-3-3 proteins as potential oncogenes. Sem Cancer Biol 2006; 16: 203-213.
48. Yang X, Cao W, Zhang L, Zhang W, Zhang X, Lin H. Targeting 14-3-3zeta in cancer therapy. Cancer Gene Ther 2012; 19: 153-159.
49. Littler DR, Alvarez-Fernandez M, Stein A, Hibbert RG, Heidebrecht T, Aloy P et al. Structure of the FoxM1 DNA-recognition domain bound to a promoter sequence. Nuc Acid Res 2010; 38: 4527-4538.
50. McGovern UB, Francis RE, Peck B, Guest SK, Wang J, Myatt SS et al. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther 2009; 8: 582-591.
51. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: Oncogene and non-oncogene addiction. Cell 2009; 136: 823-837.
52. Vera-Ramirez L, Sanchez-Rovira P, Ramirez-Tortosa MC, Ramirez-Tortosa CL, Granados-Principal S, Lorente JA et al. Free radicals in breast carcinogenesis, breast cancer progression and cancer stem cells. biological bases to develop oxidative-based therapies. Critical Reviews in Oncology/Hematology 2011; 80: 347-368.
53. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al. ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell 2007; 1: 555-567.
54. Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008; 27: 6120-6130.
55. Gemenetzidis E, Elena-Costea D, Parkinson EK, Waseem A, Wan H, Teh M-T. Induction of human epithelial stem/progenitor expansion by FOXM1. Cancer Res 2010; 70: 9515-9526.
56. OToole TE, Bialkowska K, Li X, Fox JEB. Tiam1 is recruited to b1-integrin complexes by 14-3-3z where it mediates integrin-induced Rac1 activation and motility. J Cell Physiol 2011; 226: 2965-2978.